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Introduction
The term prognosis refers to the likelihood of future 
health outcomes in people with a given disease or health 
condition or with particular characteristics such as age, 
sex, or genetic profile. Patients and healthcare providers 
may be interested in prognosis for several reasons, so 
prognostic studies may have a variety of purposes,1–4 
including establishing typical prognosis in a broad pop-
ulation, establishing the effect of patients’ characteris-
tics on prognosis, and developing a prognostic model 
(often referred to as a clinical prediction rule) (Table 1). 
Considerations in determining the trustworthiness of 
estimates of prognosis arising from these types of stud-
ies differ. This article covers studies answering ques-
tions about the prognosis of a typical patient from a 
broadly defined population; we will consider prognostic 
studies assessing risk factors and clinical prediction 
guides in subsequent papers.
Knowing the likely course of their disease may help 
patients to come to terms with, and plan for, the future. 
Knowledge of the risk of adverse outcomes or the likeli-
hood of spontaneous resolution of symptoms is critical 
in predicting the likely effect of treatment and planning 
diagnostic investigations.5 If the probability of facing an 
adverse outcome is very low or the spontaneous remis-
sion of the disease is high (“good prognosis”), the pos-
sible absolute benefits of treatment will inevitably be 
low and serious adverse effects related to treatment or 
invasive diagnostic tests, even if rare, will loom large in 
any decision. If instead the probability of an adverse 
outcome is high (“bad prognosis”), the impact of new 
diagnostic information or of effective treatment may be 
large and patients may be ready to accept higher risks 
of  diagnostic investigation and treatment related 
adverse effects.
Inquiry into the credibility or trustworthiness of 
prognostic estimates has, to date, largely focused on 
individual studies of prognosis. Systematic reviews of 
the highest quality evidence including all the prognos-
tic studies assessing a particular clinical situation are, 
however, gaining increasing attention, including 
the  Cochrane Collaboration’s work (in progress) to 
define a template for reviews of prognostic studies 
(http://prognosismethods.cochrane.org/scope-our-
work). Trustworthy systematic reviews will not only 
ensure comprehensive collection, summarization, and 
critique of the primary studies but will also conduct 
optimal analyses. Matters that warrant consideration in 
such analyses include the method used to pool rates 
and whether analyses account for all the relevant 
covariates; the literature provides guidance on both 
questions.6 7 In this article, we consider how to establish 
degree of confidence in estimates from such bodies 
of evidence.
The guidance in this article is directed primarily at 
researchers conducting systematic reviews of prognos-
tic studies. It will also be useful to anyone interested in 
prognostic estimates and their associated confidence 
(including guideline developers) when evaluating a 
body of evidence (for example, a guideline panel using 
baseline risk estimates to estimate the absolute effect of 
Summary poIntS
main concepts
The Grades of Recommendation, Assessment, Development, and Evaluation 
(GRADE) approach defines quality of evidence as confidence in effect estimates; 
this conceptualization can readily be applied to bodies of evidence estimating the 
risk of future of events (that is, prognosis) in broadly defined populations
In the field of prognosis, a body of observational evidence (including single arms of 
randomized controlled trials) begins as high quality evidence
The five domains GRADE considers in rating down confidence in estimates of 
treatment effect—that is, risk of bias, imprecision, inconsistency, indirectness, and 
publication bias—as well as the GRADE criteria for rating up quality, also apply to 
estimates of the risk of future of events from a body of prognostic studies
Applying these concepts to systematic reviews of prognostic studies provides a 
useful approach to determine confidence in estimates of overall prognosis in broad 
populations
Lay summary
The Grading of Recommendations, Assessment, Development and Evaluation 
(GRADE) approach to rating confidence in the results of research studies was 
initially developed for therapeutic questions
The GRADE approach considers study design (randomized trials versus non-
randomized designs), risk of bias, inconsistency, imprecision, indirectness, and 
publication bias; size and trend in the effect are also considered
Observational studies looking at patients’ prognosis may provide robust estimates 
of the likelihood of undesirable or desirable outcomes in both treated and 
untreated patients
Patients will often find this information helpful in understanding the likely course of 
their disease, in planning their future, and in engaging in shared decision making 
with their healthcare providers
In a previous article, we examined factors that affect confidence in estimates of 
baseline risk (the risk of bad outcomes in untreated patients), providing examples 
of how this might influence the confidence in estimates of absolute treatment effect
This paper provides guidance for the use of the GRADE approach to determine 
confidence in estimates of future events in systematic reviews of prognostic studies 
in broad categories of patients
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an intervention). People using this article to evaluate an 
existing systematic review of prognosis may find that 
the authors did not provide all the necessary informa-
tion; they may therefore need to consult the primary 
studies included in the review.
applying GraDE principles to therapeutic and 
prognostic questions
The Grades of Recommendation, Assessment, Develop-
ment, and Evaluation (GRADE) approach was devel-
oped to facilitate the production of trustworthy clinical 
practice guidelines. This requires rating the confidence 
in estimates (quality of evidence) of the effect of inter-
ventions on outcomes important to patients and then 
applying this information to determine the direction 
and strength of a management recommendation.8 In 
brief, the GRADE approach to rating confidence in esti-
mates of a body of evidence for therapeutic interven-
tions firstly considers study design: a body of 
randomized control trials begins as high quality, 
whereas a body of observational studies begins as low 
quality. The approach then involves consideration of 
five domains that may diminish confidence (rating 
down)—risk of bias, inconsistency, imprecision, indi-
rectness, and publication bias—and three situations in 
which confidence might be increased (rating up)—large 
effect, dose response gradient, and direction of plausi-
ble confounding. Depending on the study design and 
presence of these factors and consequent rating down 
or rating up, confidence is ultimately designated as 
high, moderate, low, or very low. Full details of the 
GRADE approach for evidence about treatments can be 
found in a series of articles published in the Journal of 
Clinical Epidemiology.9
The initial development of the GRADE approach 
focused exclusively on the effect of alternative manage-
ment strategies (approaches to treatment, screening, 
and more recently diagnosis) on outcomes important to 
patients. GRADE principles may also be applied to prog-
nostic studies answering several questions. One set of 
questions deals with overall prognosis in a broad popu-
lation of patients—the topic of this article. Other possi-
ble questions include establishing the characteristics of 
patients (prognostic factors) that, within a population, 
increase or decrease the risk of an event. A third cate-
gory of questions is about estimation of individual risk 
by properly developed and tested clinical prediction 
rules. Additional details on these three typologies of 
studies are provided in Table 1 and in a series of recent 
papers from the PROGRESS working group.1–4
In a previous paper, we described how the principles 
of the GRADE approach might be applied to judging our 
confidence in estimates of baseline risk needed for 
appraising the absolute effects of management options 
on outcomes important to patients.10 This is essentially 
the same question that this article covers, framed here 
as the overall prognosis in a broad group of patients. In 
this article, we provide detailed guidance for applying 
criteria to decide on certainty in estimates of prognosis 
in a broad population of patients. This paper provides 
specific guidance on the five domains proposed by 
GRADE as source of limitations that may decrease con-
fidence in estimates of overall prognosis. We will use 
examples from several systematic reviews to illustrate 
principles in application of GRADE to bodies of evi-
dence on prognosis in broad populations (Table 2) and 
describe how to summarize the output of this process in 
an evidence profile.11 12 Table 3 presents the GRADE 
interpretation of its four levels of evidence applied to 
prognostic studies.
risk of bias
Considerations of ideal study design
In contrast to questions of treatment, in which the 
GRADE approach specifies that a body of randomized 
controlled trials begins as high quality evidence and a 
body of observational evidence as low quality, in the 
field of prognosis a body of longitudinal cohort studies 
initially provides high confidence. Evidence about 
Table 1 | Types and goals of prognostic studies
Study type Study goal
Examples in field of atrial 
fibrillation
Overall prognosis Establish typical risk in broadly defined 
population*
Risk of bleeding in patients 
with atrial fibrillation 
receiving vitamin K 
antagonists
Prognostic factor Establish how particular characteristics of 
patients influence risk
Influence of age on risk of 
bleeding in patients with 
atrial fibrillation
Outcome (or risk) 
prediction model
Development of full prognostic model, 
simultaneously considering several 
prognostic factors and classifying patients 
into various levels of risk
CHADS2 and CHADS-VASC for 
risk of stroke; HAS-BLED, 
HEMORRHAGE for risk of 
bleeding
*It is equally important to estimate likelihood of spontaneous resolution of disease, as discussed in Matthew 
Thompson et al.5
Table 2 | Systematic reviews selected to assess application of GRADE to body of prognostic studies
Studies
Item(s) commented onReference Disease Outcome Design No No of patients
Lopes et al13 Atrial fibrillation Bleeding Any 51 342 699 Risk of bias, inconsistency
Arcelus et al19 Eating disorders Death Observational 36 17 272 Risk of bias, indirectness
Mohan et al20 First stroke Stroke recurrence Observational 13 9155 Risk of bias, imprecision, trend
Januel et al22 Orthopedic surgery Venous thromboembolism Any 47 44 844 Risk of bias, indirectness
Yousef et al21 Barrett’s esophagus Cancer Observational 47 11 279 Risk of bias, inconsistency, 
publication bias
Su et al26 Hemodialysis Hepatitis C virus infection Observational 22 34 060* Inconsistency, imprecision, 
indirectness
Oldenburg et al32 Mild hemophilia Inhibitor Observational 4 912 Large effect
*Person years; number of patients not reported.
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prognosis may originate from single arms of random-
ized control trials, as these could be conceptualized as 
two single arm observational studies (one being the 
intervention group, the other control group). When no 
comparison is being made—that is, when rates mea-
sured in one or the other arm, rather than the compari-
son, is the matter of interest—the distinction between 
the two designs loses much of its relevance.
In general, however, we will be more confident of 
estimates of prognosis from observational studies than 
from randomized controlled trials. The reason for the 
higher confidence in observational studies is that eligi-
bility criteria for randomized trials usually include fil-
ters (for example, restrictions in age, comorbidity, drug 
intolerance) that exclude patients who are relevant to 
the prognostic question of interest. Moreover, eligible 
patients may decline to participate in a randomized 
trial, and their reasons for declining may be related to 
their prognosis.
An exception to the general rule that randomized 
controlled trials are less trustworthy sources of evi-
dence for prognosis are large, simple, pragmatic trials 
with broad eligibility criteria that may enroll typical 
patient populations leading to trustworthy estimates of 
prognosis. For example, consider a systematic review of 
the frequency of bleeding complications in patients 
treated with vitamin K antagonists.13 The authors found 
that risk estimates from small and middle size random-
ized controlled trials were lower (1.80 (interquartile 
range 1.36–2.50) per patient year) than those from large 
observational studies (median 2.68 (1.75–4.40)) and 
large randomized controlled trials (3.09 (2.20–3.36)). 
Risk estimates from observational studies and large 
pragmatic randomized controlled trials were very simi-
lar, suggesting that large pragmatic trials—in contrast 
to smaller randomized controlled trials—enrolled repre-
sentative patient populations.
Criteria and tools
In the evaluation of risk of bias, we are concerned about 
limitations in study design and execution of individual 
studies that may result in overestimates or underesti-
mates of event rates. For example, suboptimal com-
pleteness of follow-up may lead to underestimation of 
incidence rates; misidentification of prevalent cases as 
incident cases leads to overestimation of incidence. 
 Different instruments for evaluation of risk of bias in 
prognostic studies exist, including the Quality in Prog-
nosis Study (QUIPS)14 and a modified version of the 
Newcastle Ottawa instrument.15 16 Chapter 13 of the 
Cochrane Handbook for Systematic Reviews provides 
additional guidance.17 Although all of these instruments 
may be useful, they must be tailored to each of the pos-
sible specific goals of prognostic studies as discussed 
above and in Table 1. For example, adjustment for prog-
nostic balance, crucial for establishing the effect of an 
exposure or intervention, is unimportant in assessing 
evidence about overall prognosis of broad populations.
In developing our guidance for risk of bias, we 
focused on the key concepts outlined in the Users’ 
Guides to the Medical Literature18 and summarized in 
the box. These criteria include the definition and repre-
sentativeness of the population, completeness of fol-
low-up, and objective and unbiased measurement of 
outcome. The ultimate goal is to make the quality 
assessment transparent and structured. As some degree 
of subjectivity is unavoidable, authors must clearly doc-
ument the rationale for any decision regarding rating 
down or up.
Examples from systematic reviews
Arcelus et al evaluated the rate of suicide in patients 
with eating disorders.19 Among the 36 included studies, 
spanning from 1966 to 2010, the diagnostic definition 
changed substantially over time, making the pooled 
population unlikely to be representative of patients 
meeting current diagnostic criteria. Limitations of some 
studies included unclear reporting of duration of fol-
low-up, possible missed suicides (deaths from suicide 
not classified as such), and migration of patients from 
one disease category to another (anorexia, bulimia, 
associated psychiatric disorders). These serious limita-
tions warrant rating down for risk of bias.
Another systematic review exploring the risk of 
recurrence after a first stroke, with a follow-up of 10 
years,20 also provides examples of design limitations 
sufficiently serious to warrant rating down for risk of 
bias. The definition of stroke recurrence in the individ-
ual studies was not always clear, and, even when 
clearly defined, it differed considerably among the 
CRITERIA fOR ASSESSmENT Of RISk Of bIAS
Primary
•	Was there a representative and well defined sample of patients:
– Who did not have the outcome of interest at the time of initial observation?
–  Who were at a similar, identifiable, common, and possible early point in the 
course of the disease?
•	Was follow-up sufficiently long and complete?
Secondary
•	Were objective and unbiased outcome criteria used?
•	Were all characteristics of patients known or suspected to affect the outcome 
recorded?
•	Was there adjustment for important prognostic factors?
Table 3 | Definitions of levels of evidence for typical risk of broadly defined population
Quality level Definition
High We are very confident that the true prognosis (probability of future events) lies close 
to that of the estimate*
Moderate We are moderately confident that the true prognosis (probability of future events) is 
likely to be close to the estimate, but there is a possibility that it is substantially 
different
Low Our confidence in the estimate is limited: the true prognosis (probability of future 
events) may be substantially different from the estimate
Very low We have very little confidence in the estimate: the true prognosis (probability of 
future events) is likely to be substantially different from the estimate
*Prognostic studies measure incidence—that is, target events over time in a population of interest at risk for the 
target event. The target event can be an adverse outcome (such as mortality) in patients with the disease of 
interest (for example, recent onset of atrial fibrillation) or the onset of a disease of interest (such as gastric ulcer) 
in a previously unaffected population. It can also be time to the spontaneous disappearance of a symptom 
(cough in upper airways or earache in children). Studies assessing prevalence—that is, the number of affected 
cases in the population of interest—although investigating a similar and complementary topic, are generally 
cross sectional and will be covered in a separate paper.
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studies: not all studies distinguished ischemic and 
hemorrhagic strokes; some included subarachnoid 
hemorrhage, and some did not. In addition, the stud-
ies span 50 years, and changes in the diagnosis and 
management of stroke likely had an effect on the 
course of the disease. Also, serious underestimates of 
the event rate were likely because events occurring 
within 21–28 days after a first stroke were not 
accounted for in some of the studies, as the authors 
thought that distinguishing new events from evolution 
of the first one was difficult. Therefore, we have lower 
confidence in estimates of recurrence at the earlier 
assessments (one month and one year) than for later 
ones (five and 10 years).
Sensitivity analysis
Investigators assessing the incidence rate of esophageal 
cancer in patients with Barrett’s esophagus,21 a dysplas-
tic condition that is a precursor to esophageal cancer, 
found substantial heterogeneity across studies (I2=66%, 
95% confidence interval 55% to 75%). They had, how-
ever, made the very reasonable postulate that the rigor 
of the diagnosis of Barrett’s esophagus would explain 
most of the variability. They found that this was the 
case: examination of the subsets of studies with (I2=0) 
and without (I2=72%, 60% to 80%) a standardized diag-
nosis resolved the problem of heterogeneity.
As is the case when judging confidence in estimates 
in therapy, evaluation of confidence in prognostic esti-
mates presents challenges when risk of bias varies 
across studies. Inclusion of one or more studies with 
high risk of bias does not necessarily mean one should 
rate down confidence in the pooled estimate when, for 
example, these studies contributed only a small propor-
tion of the events to the pooled event rate.
In addition, risk of bias is just that—a risk that may or 
may not result in important bias. If investigators show 
that results are similar in the studies at lower and 
higher risk of bias, we may reasonably infer that the 
limitations of the weaker studies did not in fact impor-
tantly bias the results.
Sensitivity analyses may, however, suggest that risk 
of bias is influencing estimates of prognosis. In the 
example cited above,21 studies enrolling possibly 
unrepresentative populations reported a doubling of 
the estimate of the incidence of cancer in patients with 
Barrett’s esophagus (8.2 (95% confidence interval 5.3 to 
12.8) per 1000 patient years), compared with studies 
enrolling more representative populations (4.9 (3.9 to 
6.3) per 1000 patient years).
In another review,22 studies with and without con-
cerns regarding loss to follow-up produced statistically 
different estimates of the recurrence rate of venous 
thromboembolism after total hip replacement (0.31 
(0.15 to 0.47) per 100 patients for higher risk of bias 
studies and 0.91 (0.61 to 1.39) per 100 patients for lower 
risk of bias studies).
When, as in these two situations, a sensitivity analy-
sis suggests differences in estimates between studies 
with higher and lower risk of bias, we suggest, in accor-
dance with the standard GRADE approach, using the 
estimates from the lower risk of bias studies, with no 
need to rate down confidence for risk of bias.
Inconsistency
The GRADE criteria for judging inconsistency in risk 
estimates in broad populations, as with other judg-
ments, parallel the criteria for judging inconsistency in 
risk estimates for the effect of a treatment strategy 
derived from randomized controlled trials. These 
include variability in point estimates, extent of overlap 
in confidence intervals, and where point estimates lie in 
relation to decision thresholds.
Examples from systematic reviews
Lopes et al,13 investigating bleeding rates in a large 
number of observational and randomized trials of 
patients using vitamin K antagonists, found a more 
than 10-fold variation in the estimates between studies, 
for total as well as fatal bleeding, leading to I2>90%. 
The absolute rate varied from 0.65 to 7.53 per 100 patient 
years, a variation that would lead to alternative man-
agement approaches. Accordingly, this evidence war-
ranted rating down for inconsistency.
Limitations of testing heterogeneity with I2
In the study examining the likelihood of stroke recur-
rence that provided one of our risk of bias examples,20 
seven studies reported events at five years, and four 
studies reported events at 10 years. At five years, most 
of the studies still had a large population and provided 
precise individual estimates for stroke recurrence (fig 1) 
with a pooled estimate of 26.4% (20.0% to 32.8%) in a 
random effects meta-analysis; however, heterogene-
ity, as measured by I2, was very high (>95%). At 10 
years, the individual studies’ estimates were somewhat 
less precise (fig 2), with a pooled estimate of 39.2% 
  Burn
  Petty
  Hardle
  Modrego
  Hata
  Dhamoon
  Mohan
Total
29.5 (19.9 to 39.1)
29.2 (26.0 to 32.5)
32.0 (29.5 to 34.5)
26.0 (20.9 to 31.1)
35.3 (29.1 to 41.6)
18.3 (14.9 to 21.8)
16.2 (14.4 to 18.0)
26.4 (20.0 to 32.8)
675
1111
328
425
410
655
2874
0 50 100
Study Point estimate
(95% CI)
Point estimate
(95% CI)
No in
study
fig 1 | Risk of recurrent stroke at five years
  Petty
  Hardle
  Hata
  Mohan
Total
39.3 (34.9 to 43.8)
43.0 (34.5 to 51.5)
51.3 (43.8 to 58.9)
24.5 (21.2 to 27.8)
39.2 (27.2 to 51.2)
1111
328
410
2874
0 50 100
Study Point estimate
(95% CI)
Point estimate
(95% CI)
No in
study
fig 2 | Risk of recurrent stroke at 10 years
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(27.2% to 51.2%), and once again heterogeneity was 
substantial (I2>95%).
These results show the challenges of interpreting the 
I2 in the context of prognostic studies, where the 
extremely large sample sizes of the individual studies 
result in very narrow confidence intervals.23 24 Under 
these circumstances, I2 for the pooled estimate can be 
extremely high even in the presence of modest inconsis-
tency between studies. When judging inconsistency in 
such situations, extent of variation in point estimates is 
far more important; one could even argue that the I2 is 
misleading and should not be considered.
Whether the resulting variability in the confidence 
intervals of the overall pooled estimate is large enough 
to warrant rating down for inconsistency depends on 
the effect of the difference on the patient or on the 
patient’s management. For instance, a risk of stroke of 
27% at the 10 year follow-up is probably already high 
enough to warrant high concern from the patient and 
aggressive management. It seems unlikely that patients’ 
concern or management would increase appreciably 
only if the risk were truly 51%. Our judgment was that 
concern and possibly management would not differ 
across this range, and we therefore did not rate down 
for inconsistency.
Responding to inconsistency
Authors of systematic reviews should be prepared to 
face substantial inconsistency in results and therefore 
generate a priori hypotheses that may explain the het-
erogeneity they encounter. If the subgroup analyses 
subsequently show differences across categories (for 
example, studies of older versus younger patients or 
more sick versus less sick patients) and meet criteria for 
credibility—small number of hypotheses specified, a 
priori direction of observed rates, and consistent bio-
logical rationale—chance is a very unlikely explana-
tion.25 Then one generates separate estimates for the 
relevant subgroups, potentially resolving the inconsis-
tency problem. This is exactly the same process that we 
described earlier for dealing with differences in risk of 
bias, but the hypotheses here relate to clinical rather 
than methodological differences across studies.
In a review assessing the incidence rate of hepatitis C 
virus infection in patients undergoing hemodialysis,26 
investigators found considerable inconsistency across 
studies (1.47 (1.14 to 1.60) per 100 person years; 
I2=96.1%; range of estimates in individual studies 
0.33–8.05). They had, however, postulated that rates of 
hepatitis C virus infection in hemodialysis populations 
would reflect rates in the general populations from 
which the patients with renal failure arose. They found 
at meta-regression that their hypothesis accounted for 
67.9% of the heterogeneity between the studies. Divid-
ing the studies into those from developed and develop-
ing countries and populations with low and high 
prevalence of hepatitis C virus resolved the inconsis-
tency problem, producing largely non-overlapping esti-
mates of the risk of infection. Figure 3 shows that 
developed countries can anticipate an incidence rang-
ing from a minimum of 0.16 (if the prevalence of hepati-
tis C virus positivity is low at baseline) to a maximum of 
2.57 (if the prevalence of is high); developing countries 
had between a seven times higher minimum of 1.07 (low 
baseline prevalence) and a maximum of 7.19 (high base-
line prevalence).
For two reasons, sample size may represent another 
possible explanation for heterogeneity.27 Firstly, small 
sample size is more subject to publication bias because 
decisions to submit or publish small studies may be 
driven to a greater extent by the results than is true of 
large studies. Secondly, small sample size may be a 
marker for difficult to detect methodological deficien-
cies that increase bias. These considerations suggest 
the possible merit of excluding small studies when 
major differences in results between small and large 
studies exist. For example, the previously cited system-
atic review by Yousef et al included 23 small and 24 
large studies.21 The smaller studies resulted in a much 
higher rate of cancer than did the larger ones (11.6 (8.4 
to 16) per 100 patient years versus 4.4 (3.4 to 5.7) per 
1000); the latter lower estimate may be more trust-
worthy. How important these so-called “small study 
effects” are in the field of prognosis will need further 
exploration.
Imprecision
Judgments of imprecision of risk estimates are based on 
the width of the 95% confidence interval around the 
pooled estimate and the position of the confidence 
interval relative to a clinical decision threshold. The 
GRADE rule for prognosis is to rate down confidence in 
estimates of the event rate if the effect on the patient, or 
clinical action, would differ depending on whether the 
upper or the lower boundary of the confidence interval 
represented the truth.
To illustrate the principle, imagine you are responsi-
ble for a cancer program and want to offer intensive 
 follow-up for all patients at a risk higher than 10 per 
1000 of developing a cancer. You are considering the 
previously described systematic review assessing the 
risk for esophageal cancer in patients with Barrett’s 
esophagus.21 The estimate of risk crosses the 10 per 
thousand risk cut-off in men (10.2 (6.3 to 16.4) per 1000 
patient years, calculated on the basis of 31 cases and 
3445 patient years of observation) thus leaving uncer-
tainty in the decision: if the lower boundary represents 
the truth you would not follow-up intensively, but if the 
upper boundary does then you would. Thus, in this situ-
ation one would rate down confidence for imprecision.
Among the pre-defined subgroups, you now consider 
patients with short segment Barrett’s esophagus. In this 
Developed setting and baseline HCV prevalence <15
Developed setting and baseline HCV prevalence >15
Developing setting and baseline HCV prevalence <15
Developing setting and baseline HCV prevalence >15
0.38 (0.16 to 0.59)
1.71 (0.85 to 2.57)
2.00 (1.07 to 2.93)
6.10 (5.02 to 7.19)
0 4 8
Subgroup Point estimate
(95% CI)
Point estimate
(95% CI)
fig 3 | Risk of hepatitis C virus infection in hemodialysis patients
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subgroup, the lowest risk of bias studies provide a point 
estimate of 3.9 per 1000 patient years, with a 95% confi-
dence interval from 3.0 to 5.2, on the basis of 51 cases 
and 13 677 person years of observation. In this situation, 
both upper and lower margins of the confidence inter-
val are below your threshold, so you do not need to rate 
down for imprecision.
It is not, however, in the purview of authors of sys-
tematic reviews to make decisions about the appropri-
ate threshold of risk before intensive follow-up is 
warranted—that should be left to guideline developers. 
What systematic reviewers can do is point out the impli-
cations of the evidence for decision makers. For exam-
ple, for the Barrett’s esophagus screening problem, 
they could point out that for men, for any clinical man-
agement thresholds above 16 per 1000 (the approxi-
mate upper boundary of the confidence interval), 
imprecision is not a problem. For those with short seg-
ment Barrett’s esophagus, the same is true for any 
threshold above 5 per 1000.
Indirectness
Authors of systematic reviews need to consider whether 
the studied population corresponds to their population 
of interest and whether the measured outcome captures 
what they believe is important. GRADE refers to these 
questions, sometimes labeled as generalizability or 
applicability, as questions of directness.
Consider again the systematic review assessing the 
frequency of suicide in patients with eating disorders.19 
Imagine a psychiatrist facing the parents of a young 
woman with uncomplicated anorexia not taking any 
medications, who are concerned about the likelihood 
of suicide in their daughter. Using the systematic 
review as a source of evidence, the psychiatrist would 
find that most of the patients included in the source 
studies were diagnosed as having both eating disor-
ders and other psychiatric disorders, were taking psy-
choactive medication, or reported drug addiction. The 
psychiatrist might reasonably presume that suicide 
rates would be different in uncomplicated patients and 
would therefore be reluctant to apply the results to her 
patient. Had the systematic review of suicide in 
patients with eating disorder provided separate esti-
mates for both uncomplicated and complicated 
patients, and had those estimates differed substan-
tially, the psychiatrist would have relied on estimates 
from the former population with no need to reduce 
confidence because of indirectness.
Another example of possible indirectness of popula-
tion is found in a study of rates of venous thromboem-
bolism after hip or knee surgery.22 Here, the authors 
focus only on in-hospital events. The results provide 
only indirect evidence of the overall risk, including 
events happening after discharge.
The review of hepatitis C infection in dialysis patients 
provides an example of indirectness related to out-
come.26 All included studies were conducted before 
2006, when testing was based on enzyme-linked immu-
nosorbant assay (ELISA); ELISA is reasonably accurate, 
but in the setting of hemodialysis direct viral DNA 
 testing by polymerase chain reaction (PCR) is much 
more sensitive and less affected by hemodilution.28 29 
The viral rates reported in the study provide only indi-
rect evidence regarding the true incidence of infection—
presumably this is greater, as we now know that ELISAs 
can result in a significant number of false negatives, but 
how much greater remains uncertain.
With respect to indirectness, authors of systematic 
reviews should consider the range of decision makers 
who will be using their data. For example, the authors 
of the systematic review on suicide in eating disorders 
should be aware that their results have limited applica-
bility to patients with eating disorders without import-
ant comorbidities and that such patients are an 
important subpopulation.19 The authors of the hepatitis 
C prevalence review should note that the incidence of 
diagnosed infection would likely be higher with cur-
rently available testing and that this will certainly be 
important to people making decisions on the basis of 
the evidence.26
publication bias
The systematic review of Yousef et al,21 already dis-
cussed for imprecision, is a good example of possible 
publication bias; small studies reported higher rates, 
suggesting the selective publication of “positive” stud-
ies. One might, however, imagine situations in which 
papers reporting unusually high or low rates of events 
(outlier cohorts, such as surgical cohorts in which 
patients do particularly well) are more likely to get pub-
lished.
Most commonly used statistical tests (for example, 
Egger’s test30) for publication bias are applicable when 
heterogeneity is low and data are normally distributed. 
As proportions reported in observational studies usu-
ally have an asymmetric distribution and inconsistency 
of results is often high, the use of these instruments is 
usually not appropriate. As an alternative, tests based 
on ranking (for example, Begg’s test,31) may be useful.
rating up confidence
The GRADE criteria for rating up confidence in treat-
ment studies include large effect, a dose-response gra-
dient, and situations in which all plausible confounders 
or biases would decrease an apparent treatment effect 
or would create a spurious effect when results suggest 
no effect. Analogous situations might exist for the first 
two of these in prognosis systematic reviews.
An increase in events over time following a well 
defined pattern (linear or otherwise) would increase 
confidence in any one of the data points contributing to 
the linear pattern. Figure 4 depicts such a situation in 
estimates of stroke recurrence from Mohan et al20; only 
one study directly contributed to the estimates at two 
years, but our confidence in the estimates increases 
because they all fall very close to the trend line calcu-
lated from the entire dataset.
An example of rating up for large effect comes from 
the body of evidence assessing the risk of developing 
inhibitors to therapeutic factor VIII used to prevent 
bleeding in mild hemophilia,32 which is associated with 
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a high risk of bleeding spontaneously into joint, mus-
cles, and vital organs. Data from an international regis-
try indicate that, in patients with specific causative 
mutations, the risk of developing inhibitors to factor 
VIII is likely higher than 30% with a lower bound of the 
estimate as high as 20% (fig 5). If we believe that all or 
almost all patients with a risk of inhibitor development 
of substantially greater than 2–5% (the mean risk) 
would choose an alternative treatment without any risk 
of inducing inhibitors (such as 1-desamino-8-D-arginine 
vasopressin), despite lower efficacy and the many incon-
venient side effects, we may consider rating up the 
 otherwise very low confidence in our estimates for these 
patients with specific mutations.
Thus far, we cannot envision a theoretical basis for 
the third GRADE criterion for rating up related to the 
nature of plausible biases. That said, as we continue to 
refine the GRADE approach to prognostic studies, other 
reasons to rate up confidence in estimates may arise.
Final remarks and future developments
Adopted by more than 70 healthcare organizations, the 
GRADE approach focuses on evaluating confidence in 
estimates of the effect of one treatment strategy over an 
alternative. In this article, we have shown that these 
same principles work well in assessing bodies of evi-
dence regarding overall prognosis in broad groups of 
patients. Challenges in defining criteria and providing 
guidance do, however, remain.
One of these challenges is the gray area between risk 
of bias and indirectness of evidence. In our suggested 
framework, extrapolating the estimate obtained in a 
representative population to a different population or to 
a specific subgroup is a matter of indirectness, whereas 
recruiting a non-representative population falls in the 
risk of bias domain. In other words, when a study sam-
ple is representative of the underlying population 
defined in the study question but does not match the 
population of interest for a specific clinical question 
posed by a systematic review author or guideline devel-
oper, the question is one of indirectness. When the sam-
ple is not representative of the underlying population, 
because of either limitations in the selection process of 
an observational study or the patient selection involved 
in a randomized controlled trial, the relevant domain is 
risk of bias. Although we have tried to clarify this, gray 
areas may exist in which the distinction raises a chal-
lenging matter of judgment.
One could argue, however, that regardless of catego-
rization (that is, risk of bias or indirectness) what mat-
ters most is the overall assessment of the confidence in 
the prognostic estimates. In this case, the distinction 
becomes less crucial. The goal is to ensure that readers 
understand the nature of the question: providing a 
transparent rationale for judgments will likely achieve 
that objective.
A second challenging problem arises in the context of 
random effects pooled estimates of effect with large dif-
ferences in effect between studies. Using random effects 
models results in appropriately wider confidence inter-
vals associated with large between study variation 
Authors of systematic reviews may firstly rate down for 
inconsistency and then, because of the wide confidence 
intervals, rate down for imprecision. The risk is double 
counting inconsistency and imprecision and conse-
quently attributing an excessively low rating of confi-
dence. Systematic review authors should be alert to the 
risk of such double counting and remember that judg-
ments of confidence in prognostic estimates should not 
be done mechanistically. Rather, these judgments 
should be based on an overall assessment of the confi-
dence in prognostic estimates across the five factors 
that might decrease confidence.
Despite these challenges, applying the GRADE prin-
ciples for rating confidence in estimates can provide 
explicit, transparent, and rigorous standards for deter-
mining the strength of inferences from bodies of evi-
dence on prognosis in broadly defined populations.
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